consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before December 13, 1999.

ADDRESSES: Comments should be directed to: FTC/Office of the Secretary, Room 159, 600 Pennsylvania Ave., NW, Washington, DC 20580.

FOR FURTHER INFORMATION CONTACT: Linda Badger, Kerry O'Brien or Matthew Gold, Federal Trade Commission, Western Regional Office, 901 Market St., Suite 570, San Francisco, CA 94103. (415) 356–5270.

SUPPLEMENTARY INFORMATION: Pursuant to section 6(f) of the Federal Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46 and section 2.34 of the Commission's Rules of Practice (16 CFR 2.34), notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of sixty (60) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC Home Page (for September 15, 1999), on the World Wide Web, at ''htt;:// www.ftc.gov/os/actions97.htm.'' A paper copy can be obtained from the FTC Public Reference Room, Room H–130, 600 Pennsylvania Avenue, NW, Washington, DC 20580, either in person or by calling (202) 326–3627.

Public comment is invited. Comments should be directed to: FTC/Office of the Secretary, Room 159, 600 Pennsylvania Ave., NW, Washington, DC 20580. Two paper copies of each comment should be filed, and should be accompanied, if possible, by a 3½ inch diskette containing an electronic copy of the comment. Such comments or views will be considered by the Commission and will be available for inspection and copying at its principal office in accordance with section 4.9(b)(6)(ii) of the Commission's Rules of Practice (16 CFR 4.9(b)(6)(ii)).

Analysis of Proposed Consent Order To Aid Public Comment

The Federal Trade Commission has accepted an agreement, subject to final approval, to a proposed consent order from Conopco, Inc. (''Conopco''). Through its numerous divisions, such as Unilever Home & Personal Care USA, Conopco manufactures and markets a large line of home and personal care products.

The proposed consent order has been placed on the public record for sixty (60) days for the reception of comments by interested persons. Comments received during this period will become part of the public record. After sixty (60) days, the Commission will again review the agreement and any comments received and will decide whether it should withdraw from the agreement and take other appropriate action or make final the agreement's proposed order.

This matter has focused on Conopco's advertisements for Vaseline Brand Intensive Care Antibacterial Hand Lotion (''VOCAL''). The Commission's complaint challenges claims made in television, print, and product label advertisements. Specifically, the complaint alleges that Conopco lacked substantiation for its claims that VICAL: (1) Stops germs on hands longer than washing alone; (2) Provides continuous protection from germs for hours; and (3) Is effective against disease-causing germs, such as cold and flu viruses. According to the complaint, while VICAL can reduce the number of germs on a user's hands, the degree and duration of germ protection have not been scientifically established. Also, according to the complaint, VICAL has not been proven effective against many disease-causing germs, including cold and flu viruses, which are the cause of the most common diseases suffered by consumers.

The proposed consent order contains provisions designed to remedy the violations charged and to prevent the respondent from engaging in similar acts and practices in the future. Part I of the proposed order would require that Conopco possess and rely upon competent and reliable scientific evidence for any claim that VICAL or any other antimicrobial product: (1) Is as effective as, or is more effective than, washing alone in protecting users against germs; (2) has a continuous effect against germs; (3) has any effect on any specific germ; and (4) treats, cures, alleviates the symptoms of, prevents, or reduces the risk of developing any disease or disorder, such as colds, allergies, influenza, or food-borne illnesses. As set out in Part III of the proposed order, Part I will not apply to any product sold or distributed to consumers by third parties under private labeling agreements with Conopco provided, Conopco does not participate in any manner in the funding, preparation or dissemination of the product's advertising.

Part II of the proposed order contains language permitting Conopco to make drug claims that have been approved by the FDA pursuant to either a new drug application or a tentative final or final standard.

The proposed order requires Conopco to maintain materials relied upon to substantiate claims covered by the order; to provide a copy of the consent agreement to all employees or representatives with duties affecting compliance with the terms of the order; to notify the Commission of any changes in corporate structure that might affect compliance with the order; and to file one or more reports detailing compliance with the order.

The purpose of this analysis is to facilitate public comment on the proposed order, and it is not intended to constitute an official interpretation of the agreement and proposed order, or to modify in any way their terms.

By direction of the Commission.

Benjamin I. Berman,

Acting Secretary.

[FR Doc. 99–26844 Filed 10–13–99; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Statement of Organization, Functions and Delegations of Authority; Program Support Center

Part P (Program Support Center) of the Statement of Organization, Functions and Delegations of Authority for the Department of Health and Human Services (HHS), (60 FR 51480, October 2, 1995 as amended most recently at 64 FR 34809, June 29, 1999) is amended to reflect changes in Chapter PA within Part P, Program Support Center (PSC), HHS. The PSC is reorganizing to consolidate and streamline functions within the Office of the Director. The *Office of Management Operations* is being abolished and its functions are being realigned within the *Office of Marketing*, the *Office of Budget and Management* (formerly the *Office of Budget and Finance*), and the *Immediate Office of the Director.*

Program Support Center

Under *Part P, Section P–20, Functions,* change the following:

Under *Chapter PA, Office of the Director (PA),* retitle the *Office of Budget and Finance (PA2)* as the *Office of Budget and Management (PAB).* Add the following new items after item (10): ''(11) Develops, coordinates, and implements policies, standards, and procedures governing the administration of the PSC delegations of authority; (12) Develops, coordinates,

and implements policies, standards, and procedures governing the establishment and maintenance of effective organizational structures and functional alignments within the PSC; (13) Administers the Standard Administrative Code (SAC) system for the PSC; (14) Monitors, evaluates, and controls the preparation of PSC responses and proposed HHS responses to PSC-related OIG reports (including internal reviews, analyses and inspections, and investigations); and (15) Coordinates the implementation of the Government Performance and Results Act within the PSC.''

Under the heading, *Office of Marketing (PAC)* (formerly PA3) add the following new items after item (4): ''(5) Coordinates and implements HHS policies and procedures regarding the Privacy Act of 1974, Freedom of Information Act, and the Paperwork Reduction Act of 1995 for the PSC; and (6) Coordinates the PSC-wide policy and procedures system utilizing the PSC Intranet.''

Delete the title and functional statement for the *Office of Management Operations (PA5)* in its entirety.

Dated: October 1, 1999.

Lynnda M. Regan,

Director, Program Support Center.

[FR Doc. 99–26718 Filed 10–13–99; 8:45 am]

BILLING CODE 4168–17–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30DAY–03–00]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639–7090. Send written comments to CDC, Desk Officer; Human Resources and Housing Branch, New Executive Office Building, Room 10235; Washington, DC 20503. Written comments should be received within 30 days of this notice.

Proposed Project

1. An Evaluation of Targeted Health Communication Messages: Folic Acid and Neural Tube Defects—NEW—National Center for Environmental Health (NCEH). The Division of Birth Defects and Pediatric Genetics, National Center for Environmental Health, CDC, launched a national education campaign in January 1999 to increase women's knowledge about neural tube birth defects (NTDs) and the beneficial role folic acid, a B vitamin, plays in the prevention of NTDs. Studies show that a 50 to 70 percent reduction in the risk of neural tube birth defects is possible if all women capable of becoming pregnant consume 400 micrograms of folic acid daily both prior to and during early pregnancy.

CDC and the March of Dimes Birth Defects Foundation developed health communication media messages and educational materials targeted to health care providers, as well as to English and Spanish-speaking women. These media messages and educational materials consist of television and radio public service announcements (PSA), brochures and resource manuals.

Information about women's exposure to media messages and educational materials on folic acid information will be collected and measured to determine whether these exposures influenced the women's knowledge and usage of folic acid. Data will be collected via telephone interviews. The number and frequency of women's exposures to the media messages such as television and radio PSAs will be collected from media channels and compared to information collected from survey data, National Council on Folic Acid organizations and the National Clearinghouse on Folic Acid activities. The total annual burden hours are 534.

Respondents	Number of respondents	Number of responses/respondent	Average burden/response (in hours)
Targeted Market for the Folic Acid Messages	2,000	1	.33

Nancy Cheal,

Acting Associate Director for Policy Planning and Evaluation, Centers for Disease Control and Prevention.

[FR Doc. 99–26786 Filed 10–13–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Citizens Advisory Committee on Public Health Service Activities and Research at Department of Energy (DOE) Sites: Savannah River Site Health Effects Subcommittee

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) announce the following meeting.

Name: Citizens Advisory Committee on Public Health Service Activities and Research at DOE Sites: Savannah River Site Health Effects Subcommittee (SRSHES).

Times and Dates: 8:30 a.m.–5 p.m., November 4, 1999. 8:30 a.m.–12 noon, November 5, 1999.

Place: Holiday Inn Oceanfront, One South Forest Beach Drive, Hilton Head, South Carolina 29928, telephone 843/785–5126, fax 843/785–7753.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Background: Under a Memorandum of Understanding (MOU) signed in December 1990 with DOE and replaced by an MOU signed in 1996, the Department of Health and Human Services (HHS) was given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities, workers at DOE facilities, and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production use. HHS delegated program responsibility to CDC.

In addition, a memo was signed in October 1990 and renewed in November 1992 between ATSDR and DOE. The MOU delineates the responsibilities and procedures for ATSDR's public health activities at DOE sites required under sections 104, 105, 107, and 120 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or ''Superfund''). These activities include health consultations and public health assessments at DOE sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public; and other health-related activities such as epidemiologic studies, health surveillance, exposure and disease registries, health education, substance-specific applied research, emergency response, and preparation of toxicological profiles.

Purpose: This subcommittee is charged with providing advice and recommendations to the Director, CDC, and the Administrator, ATSDR, regarding community, American